Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07121478 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Patients With High-grade Pancreatic Neuroendocrine Tumors

StatusEnrolling by Invitation
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Active, Not Recruiting to Enrolling by Invitation
    • Start date: Jul 15, 2025 to Sep 23, 2025
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
* Pancreatic neuroendocrine tumor (pNET) is a rare form of cancer. Treatment options such as hormonal therapy (octreotide) and targeted therapy (everolimus and sunitinib) may be considered for grade 1 or 2 pNETs; however, cytotoxic chemotherapy is essential in cases with grade 3 pNETs or pNECs. * Cisplatin/etoposide remains the treatment of choice for high-grade pNET/pNEC. Other irinotecan-based therapies, such as FOLFIRI (cisplatin/irinotecan), FOLFOX, and temozolomide ± capecitabine, have been employed; however, a standard of care remains to be established.
Trial Details
NCT Number NCT07121478
Lead Sponsor National Cancer Center, Korea
Collaborators: Seoul National University Bundang Hospital, Samsung Medical Center, Seoul National Hospital, Gangnam Severance Hospital
Conditions
(from sponsor)		 Neuroendocrine Tumor of Pancreas, Pancreatic Neuroendocrine Tumors
Related terms Adenoma, Islet Cell, Neuroendocrine Tumors
Enrollment 46 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov